{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:32:08Z","timestamp":1768278728256,"version":"3.49.0"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,19]]},"DOI":"10.18632\/oncotarget.7795","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T03:32:25Z","timestamp":1456803145000},"page":"21631-21643","source":"Crossref","is-referenced-by-count":37,"title":["High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid"],"prefix":"10.18632","volume":"7","author":[{"given":"Wei","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourong","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"},{"name":"Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","article-title":"measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells","volume":"115","author":"Wasil","year":"2005","journal-title":"J Clin Invest"},{"issue":"434","key":"2","first-page":"843","article-title":"Wnt signaling in stem cells and cancer","volume":"14","author":"Clevers","year":"2005","journal-title":"Nature"},{"key":"3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1084\/jem.20071875","article-title":"A novel role for LEF-1, a central transcription mediator of Wnt signaling, in leukemogenesis","volume":"205","author":"Buske","year":"2008","journal-title":"J Exp Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1074-7613(00)80454-9","article-title":"Redundant regulation of T cell differentiation and TCR alpha gene expression by the transcription factors of LEF-1 and TCF-1","volume":"8","author":"Grosschedl","year":"1998","journal-title":"Immunity"},{"key":"5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)00004-2","article-title":"Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism","volume":"13","author":"Grosschedl","year":"2000","journal-title":"Immunity"},{"key":"6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ng.2652","article-title":"Genome-wide Association Study Identifies Multiple Risk Loci for Chronic Lymphocytic Leukemia","volume":"45","author":"Teras","year":"2013","journal-title":"Nat Genet"},{"key":"7","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2010-02-269878","article-title":"LEF1 is a prosurvival factor in chronic lymphocytic leukemia is expressed in the preleukemic state of monoclonal B-cell lymphocytosis","volume":"116","author":"Jelinek","year":"2010","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2012-02-411827","article-title":"High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia","volume":"120","author":"D\u00f6hner","year":"2012","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.18632\/oncotarget.1619","article-title":"Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia","volume":"15","author":"Specchia","year":"2014","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1182\/blood-2011-04-350850","article-title":"Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia","volume":"118","author":"Baldus","year":"2011","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood-2007-04-084202","article-title":"Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas","volume":"110","author":"Kee","year":"2007","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.leukres.2005.06.004","article-title":"Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma","volume":"30","author":"Bromidge","year":"2006","journal-title":"Leuk Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/cdd.2009.43","article-title":"CYLD: a tumor suppressor deubiquitinase regulating NF-\u03baB activation and diverse biological processes","volume":"17","author":"Sun","year":"2010","journal-title":"Cell Death Differ"},{"key":"14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature01802","article-title":"The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination","volume":"424","author":"Courtois","year":"2003","journal-title":"Nature"},{"key":"15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2011.08.004","article-title":"Necroptosis: an emerging form of programmed cell death","volume":"82","author":"Li","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.cell.2008.10.044","article-title":"Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway","volume":"135","author":"Yuan","year":"2008","journal-title":"Cell"},{"key":"17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/leu.2011.357","article-title":"Dysregulation of TNF\u03b1-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1","volume":"26","author":"Li","year":"2012","journal-title":"Leukemia"},{"key":"18","first-page":"1063","article-title":"Resistance circumventions strategies tested in clinical leukaemia specimens using the MTT colorimetric assay","volume":"6","author":"Twentyman","year":"1992","journal-title":"Leukemia"},{"key":"19","first-page":"726","article-title":"Selective toxicity of ethacrynic acid towards lymphocytes of chronic lymphocytic leukemia","volume":"6","author":"Rees","year":"1992","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-12-0770","article-title":"Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia andlymphoma cells: the role of glutathione S-transferase p1-1","volume":"18","author":"Jing","year":"2012","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0169-409X(97)00029-X","article-title":"Inhibitors of glutathione S-transferases as therapeutic agents","volume":"26","author":"Schultz","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1349-7006.2003.tb01371.x","article-title":"Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine","volume":"94","author":"Tsuchida","year":"2003","journal-title":"Cancer Sci"},{"key":"23","doi-asserted-by":"crossref","first-page":"e8294","DOI":"10.1371\/journal.pone.0008294","article-title":"Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt\/beta-catenin pathway","volume":"4","author":"Carson","year":"2009","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.4081\/hr.2010.e3","article-title":"High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in CLL","volume":"2","author":"Kreuzer","year":"2010","journal-title":"Hematol Rep"},{"key":"26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1593\/neo.91972","article-title":"Small Molecule Inhibitors of Wnt\/\u03b2-Catenin\/Lef-1Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cellsand","volume":"12","author":"Kreuzer","year":"2010","journal-title":"Neoplasia"},{"key":"27","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1080\/10428190410001714016","article-title":"Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and isassociated with, but not generally restricted to, non-mutated Ig VH status","volume":"45","author":"Weidmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"28","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Montserrat","year":"2003","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"e3909","DOI":"10.1371\/journal.pone.0003909","article-title":"Acute Myeloid Leukemia-Targeted Toxin Activates Both Apoptotic and Necroptotic Death Mechanisms","volume":"3","author":"Thorburn","year":"2008","journal-title":"PLoS One"},{"key":"30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10495-009-0334-x","article-title":"Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis","volume":"14","author":"Hu","year":"2009","journal-title":"Apoptosis"},{"key":"31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kB pathway in multiple myeloma","volume":"12","author":"Zhu","year":"2007","journal-title":"Cancer Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ccr.2010.08.006","article-title":"The Notch\/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia","volume":"18","author":"Kucine","year":"2010","journal-title":"Cancer Cell"},{"key":"33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcmd.2014.07.008","article-title":"Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia","volume":"54","author":"Marwaha","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/10428194.2013.809077","article-title":"Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia","volume":"55","author":"Li","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"35","unstructured":"Schmidt, Kim, Gast, Endo, Lu, Carson, Schmidt-Wolf. Increasedin vivoefficacy of lenalidomide and thalidomide by addition of ethacrynic acid.in vivo. 2011; 25:325\u2013333."},{"key":"36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.1993.tb03187.x","article-title":"Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient","volume":"85","author":"Ronca","year":"1993","journal-title":"Br J Haematol"},{"key":"37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2007.11.007","article-title":"Bypassing cancer drug resistance by activating multiple death pathways-A proposal from the study of circumventing cancer drug resistance by induction of necroptosis","volume":"259","author":"Xuan","year":"2008","journal-title":"Cancer Lett"},{"key":"38","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-12-3289","article-title":"Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy","volume":"19","author":"Lavitrano","year":"2013","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0022-3565(25)22526-5","article-title":"Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer","volume":"270","author":"O'Dwyer","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"40","first-page":"6059","article-title":"Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid","volume":"51","author":"Ozols","year":"1991","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:37:51Z","timestamp":1748792271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":40,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,4,19]]}},"alternative-id":["7795","26950276"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7795","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}